Histostem Participates in Preclinical Study Showing Effective Use of HMSCs in Treatment of Cirrhosis of the Liver

AmStem Corporation (OTC Bulletin Board: SCII) has announced that Histostem Ltd. of South Korea, took part in a successful preclinical study of the use of its proprietary Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells (HMSCs) in the treatment of cirrhosis of the liver.

Top Best Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move. Sign up for our Free Stock Newsletter.

The study was a joint effort from a research team in Korea, Kyung Hee University and Hanyang University in Seoul and Dongguk University in Goyang, in collaboration with Dr. Hoon Han, the President and Founder of Histostem. The clinical trial results showed that an infusion of HMSCs has the ability to inhibit the fibrosis formation and progression of cirrhosis in rats.

AmStem Corporation (OTCBB: SCII) is in the field of regenerative medicine. The Company is devoted to the treatment of patients with stem cell transplantation therapy as well as providing the supplies of biological solutions containing new lines of stem cell products.

Histostem was founded in Seoul, Korea in 2000. To date it has treated more than 500 patients with stem cells and currently has approximately 50 full-time employees and several part-time employees.

Sign up for Top Best Penny Stocks' free newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.

Follow us on Twitter: http://www.Twitter.com/topbestps

About Us

Top Best Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.

Please click here to read the full disclaimer.